195 related articles for article (PubMed ID: 10710174)
1. The use of the Panic and Agoraphobia Scale in a clinical trial.
Bandelow B; Brunner E; Broocks A; Beinroth D; Hajak G; Pralle L; Rüther E
Psychiatry Res; 1998 Jan; 77(1):43-9. PubMed ID: 10710174
[TBL] [Abstract][Full Text] [Related]
2. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients.
Bandelow B; Brunner E; Beinroth D; Pralle L; Broocks A; Hajak G; Rüther E
Eur Arch Psychiatry Clin Neurosci; 1999; 249(1):21-7. PubMed ID: 10195340
[TBL] [Abstract][Full Text] [Related]
3. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
[TBL] [Abstract][Full Text] [Related]
4. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
Marchesi C; Ampollini P; Signifredi R; Maggini C
Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale.
Furukawa TA; Katherine Shear M; Barlow DH; Gorman JM; Woods SW; Money R; Etschel E; Engel RR; Leucht S
Depress Anxiety; 2009; 26(10):922-9. PubMed ID: 19006198
[TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems.
Bandelow B; Hajak G; Holzrichter S; Kunert HJ; Rüther E
Int Clin Psychopharmacol; 1995 Jun; 10(2):83-93. PubMed ID: 7673660
[TBL] [Abstract][Full Text] [Related]
7. Assessing the severity of panic disorder and agoraphobia: validity, reliability and objectivity of the Turkish translation of the Panic and Agoraphobia Scale (P&A).
Tural U; Fidane H; Alkin T; Bandelow B
J Anxiety Disord; 2002; 16(3):331-40. PubMed ID: 12214818
[TBL] [Abstract][Full Text] [Related]
8. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N
Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313
[TBL] [Abstract][Full Text] [Related]
9. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
10. DSM-II personality characteristics of panic disorder with agoraphobia patients in stable remission.
Mavissakalian M; Hamann MS
Compr Psychiatry; 1992; 33(5):305-9. PubMed ID: 1356708
[TBL] [Abstract][Full Text] [Related]
11. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale.
Bandelow B
Int Clin Psychopharmacol; 1995 Jun; 10(2):73-81. PubMed ID: 7673659
[TBL] [Abstract][Full Text] [Related]
12. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.
Bandelow B; Broocks A; Pekrun G; George A; Meyer T; Pralle L; Bartmann U; Hillmer-Vogel U; Rüther E
Pharmacopsychiatry; 2000 Sep; 33(5):174-81. PubMed ID: 11071019
[TBL] [Abstract][Full Text] [Related]
13. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
[TBL] [Abstract][Full Text] [Related]
14. Panic Disorder Severity Scale: reliability and validity of the Turkish version.
Monkul ES; Tural U; Onur E; Fidaner H; Alkin T; Shear MK
Depress Anxiety; 2004; 20(1):8-16. PubMed ID: 15368591
[TBL] [Abstract][Full Text] [Related]
15. Panic disorder subtypes: further clinical differences.
Onur E; Alkin T; Tural U
Depress Anxiety; 2007; 24(7):479-86. PubMed ID: 17106872
[TBL] [Abstract][Full Text] [Related]
16. Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
Scheibe G; Albus M
J Affect Disord; 1996 Nov; 41(2):111-6. PubMed ID: 8961038
[TBL] [Abstract][Full Text] [Related]
17. The structure of phobias in panic disorder.
Argyle N; Solyom C; Solyom L
Br J Psychiatry; 1991 Sep; 159():378-82. PubMed ID: 1958949
[TBL] [Abstract][Full Text] [Related]
18. Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
Mavissakalian MR; Perel JM
J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900
[TBL] [Abstract][Full Text] [Related]
19. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
[TBL] [Abstract][Full Text] [Related]
20. A 15-year follow-up study of patients with panic disorder.
Andersch S; Hetta J
Eur Psychiatry; 2003 Dec; 18(8):401-8. PubMed ID: 14680716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
